Aytu offering. ENGLEWOOD, CO, August 9, 2022 - Aytu BioPharma, Inc.

Aytu offering The offering was led by healthcare-focused institutional investors including Nantahala Capital Management and Stonepine Capital Management. Putting patients first. Aug 9, 2022 · ENGLEWOOD, CO / ACCESSWIRE / August 9, 2022 / Aytu BioPharma, Inc. Jun 25, 2025 · Aytu BioPharma is a pharmaceutical company developing and commercializing novel therapeutics with a focus on pediatrics and pediatric-onset conditions. Jun 6, 2025 · In addition, Aytu has granted the underwriters a 30-day option to purchase up to an additional 1,440,000 shares of its common stock at the public offering price. Oct 11, 2018 · Aytu BioScience, Inc. Looking for the best stocks to buy? Follow the recommendations of top-performing analysts. Hassle-free. Our novel therapeutics enhance the lives of patients living with major depressive disorder (MDD) and attention deficit/hyperactivity disorder (ADHD). We ensure access to our medicines by thinking differently and acting boldly – while always putting Jun 6, 2025 · In addition, Aytu has granted the underwriters a 30-day option to purchase up to an additional 1,440,000 shares of its common stock at the public offering price. Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and Jun 9, 2025 · Gross proceeds from offering total $16. (the “Company” or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the pricing of its underwritten public offering of (i) 21,505,814 shares of its common stock, and, in lieu of common stock to certain Aug 9, 2022 · All of the securities in the Offering will be sold by Aytu. In addition, Aytu has granted the underwriters a 30-day option to purchase up to an additional 1,440,000 shares of its common stock at the public offering price. 50 and 8,233,332 prefunded Mar 3, 2022 · We operate through two business segments: the Aytu BioPharma segment, consisting of various prescription pharmaceutical products sold through third party wholesalers, and the Aytu Consumer Health segment, which consists of various consumer health products sold directly to consumers. 6 million shares at $1. 6 million, assuming none of the accompanying common warrants issued in the Offering are exercised. 4 million in gross proceeds to primarily fund the exclusive commercialization of its major depressive disorder treatment, EXXUA. In addition, in the event the warrants are exercised in full, Aytu expects to receive approximately $20 million in additional gross proceeds. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the pricing of its underwritten public offering of (i) 21,505,814 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 1,750,000 shares of its common stock Jun 9, 2025 · Gross proceeds from offering total $16. Aytu BioPharma Announces Pricing of $4. 50 per share, raising $14. Jun 6, 2025 · In addition, Aytu has granted the underwriters a 30-day option to purchase up to an additional 1,440,000 shares of its common stock at the public offering price. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the pricing of its Patient, pharmacist and prescriber agree not to seek reimbursement for all or any part of the benefit received by patient through the ofer. Armistice Capital, LLC, Delaware’s Court of Chancery dismissed a stockholder plaintiff’s derivative suit against Armistice Capital, LLC, a large investor in Aytu Biopharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the launch of an underwritten Jun 6, 2025 · In addition, Aytu has granted the underwriters a 30-day option to purchase up to an additional 1,440,000 shares of its common stock at the public offering price. 50 and 8,233,332 prefunded Jun 10, 2025 · Aytu BioPharma, Inc. Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and Aug 9, 2022 · Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ: AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced the pricing of an upsized public offering of 9,600,000 shares of common stock (or prefunded warrants in lieu thereof) at an effective public offering price of $1. 43% at $1. Jun 9, 2025 · Aytu BioPharma (AYTU), a company focused on innovative pharmaceuticals, has successfully closed an upsized at-the-market public offering, raising $16. Aug 8, 2022 · Aytu BioPharma Announces Launch of Public Offering ENGLEWOOD, CO / August 8, 2022 / Aytu BioPharma, Inc. Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and Jun 6, 2025 · In addition, Aytu has granted the underwriters a 30-day option to purchase up to an additional 1,440,000 shares of its common stock at the public offering price. Jun 9, 2025 · In addition, Aytu has granted the underwriters a 30-day option to purchase up to an additional 1,440,000 shares of its common stock at the public offering price. Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD Jun 9, 2025 · Gross proceeds from offering total $16. Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and Stonepine Capital Jun 9, 2025 · Gross proceeds from offering total $16. (the "Company" or "Aytu") (Nasdaq: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the pricing of its underwritten public offering of (i) 21,505,814 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase Aug 9, 2022 · ENGLEWOOD, CO / ACCESSWIRE / August 9, 2022 / Aytu BioPharma, Inc. DENVER, CO / ACCESS Newswire / June 9, 2025 / Aytu BioPharma, Inc. Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD Mar 3, 2022 · Aytu BioPharma Inc. 4 million in gross proceeds. Save Money with the Aytu RxConnect Program With the Aytu RxConnect program, patients with commercial insurance will NEVER pay more than a $25 co-pay for their Karbinal ER prescription. In addition, Aytu has granted the Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA (TM) Opportunity and Commercialization Plan ACCESS Newswire Jun 9, 2025, 1:30 PM Save Money with the Aytu RxConnect Program With the Aytu RxConnect program, patients with commercial insurance will NEVER pay more than a $10 co-pay for their Adzenys XR-ODT prescription. The savings offer is different for commercially insured patients that can’t participate or choose not to participate in Aytu RxConnect. Find an Aytu RxConnect Pharmacy Near You AytuRxConnect. May 30, 2025 · This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. The offering is expected to Jun 9, 2025 · Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD. 45 per unit With an established portfolio in CNS and specialty medicines, we will continue to acquire and commercialize novel products to help people lead better lives, with a distinct focus on psychiatric conditions. . patent covering the company's proprietary MiOXSYS® diagnostic platform for male infertility. Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and Stonepine Capital Management, with participation from Aytu management and new institutional shareholders. 50. is known for its commitment to delivering high-quality products that improve the lives of patients. will have the resources and expertise needed to enhance its product offerings and expand its market presence. Financing led by long-term, healthcare-focused institutional investors, including Aytu 's largest shareholders Nantahala Capital Management and Stonepine Capital Management, with participation from Aytu management and new institutional shareholders. 6 million. Aytu BioPharma, Inc. The information disclosed will include the patient copay ID, pharmacy demographics, prescriber information, and details Getting Aytu Branded Medications for as little as $0* is easier than ever. See Terms and Conditions. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced the closing of an upsized at the market public offering of 1,366,688 shares of common stock, par value $0. 0 million net income in Q3, marking a turnaround to profitability while shares rebounded over 110% from April lows. (AYTU) has plunged -5. To view this announcement, click here. This significant capital infusion, backed by institutional investors and Aytu management, positions the company for strategic growth despite substantial 3 days ago · Should You Buy or Sell Aytu BioPharma Stock? Get The Latest AYTU Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. (NASDAQ:AYTU) disclosed that it has successfully extended its lending agreement with Eclipse Business Capital LLC (“Eclipse”), offering additional working Jun 6, 2025 · Aytu BioPharma (AYTU) announced the pricing of an upsized public offering of 9,600,000 shares of common stock at an effective public offering price of $1. Gross proceeds to the Company, before deducting underwriters' fees and 2 days ago · Aytu BioPharma Announces At the Market Pricing of $14. Aytu BioPharma Inc (AYTU) develops innovative prescription therapeutics in urology and ADHD, offering advanced solutions for unmet medical needs. (the “Company” or “Aytu”) (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced the pricing of an upsized public offering of 9,600,000 shares of common stock (or prefunded warrants in lieu thereof) at an effective public offering price of $1. 2 million which includes the full exercise of the 5 days ago · Recently, in Witmer v. 50 and 8,233,332 prefunded The 1 analysts offering 12-month price forecasts for Aytu Biopharma Inc have a median target of 5. Hassle-free Tell your doctor about the Aytu RxConnect Jun 9, 2025 · Gross proceeds from offering total $16. Jun 6, 2025 · DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc. The financing was led by long-term healthcare-focused institutional investors, including Aytu's largest shareholders, Nantahala Capital Management and Stonepine Capital Management, with participation from Aytu management and new institutional shareholders. Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD AYTU - Aytu BioPharma Inc - Stock screener for investors and traders, financial visualizations. The offering is expected to close on or about June 9, 2025, subject to the satisfaction of customary closing conditions. Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and Aug 15, 2022 · Aytu BioPharma (NASDAQ:AYTU) closed its underwritten public offering, raising $10. 6 million in gross proceeds, primarily to fund the commercialization of EXXUA, its novel antidepressant, in the over $22 billion U. announced the closing of its equity offering co-led by Nantahala Capital Management and Stonepine Capital Management with participation by Armistice Capital of 1,743,695 shares of its common stock. Stay updated on key market moves and investment opportunities. 4 Million Upsized Public Offering of Common Stock Nantahala Capital Management, Stonepine Capital Management, Aytu Management, and New Institutional Shareholders Lead Financing. Jun 6, 2025 · Aytu BioPharma (NASDAQ: AYTU) made headlines today with two major announcements: the exclusive U. A total of 19,520,000 Class A Units were sold at a price of $0. Jun 9, 2025 · Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD. OR > Learn more Additional Savings Offer If you can’t find an RxConnect pharmacy near you, we still have you covered. Jun 6, 2025 · On June 5, 2025, Aytu BioPharma announced an underwriting agreement with Lake Street Capital Markets for a public offering of common stock and prefunded warrants, aiming to raise approximately $12. commercialization rights to EXXUA™ (gepirone), a first-in-class antidepressant approved by the FDA, and the pricing of a $14. This decision marks a significant increase in the company's capital-raising efforts. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the pricing of its equity offering co-led by Nantahala Capital Management and Stonepine Capital Management with participation by Armistice Capital of (i) 1,743,695 shares of its common stock, and, in lieu of Aug 15, 2022 · The aggregate gross proceeds from the Offering were $10. Aug 9, 2022 · Aytu BioPharma Announces Pricing of Public Offering ENGLEWOOD, CO / August 9, 2022 / Aytu BioPharma, Inc. (NASDAQ: AYTU) announced on 10/11/18 the issuance of a U. Our CNS product portfolio addresses major depressive disorder (MDD) and attention deficit Jun 9, 2025 · Gross proceeds from offering total $16. 50 each. (the "Company" or "Aytu") (NASDAQ: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the pricing of its underwritten public offering of (i) 21,505,814 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to Jun 9, 2025 · DENVER, CO / ACCESS Newswire / June 9, 2025 / Aytu BioPharma, Inc. 7 million shares to 9. stock news by MarketWatch. (NASDAQ: AYTU) in a $12 million public offering of Class A Units, comprising common stock and warrants and Class B Units comprising Series B Preferred Stock and Warrants. 0 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Aytu. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the pricing of its equity offering co-led by Nantahala Capital Management and Stonepine Capital Management with participation by Armistice Capital of (i) 1,743,695 shares of its common stock, and, in lieu of Oct 10, 2025 · AYTU | Complete Aytu BioPharma Inc. Jun 9, 2025 · Gross proceeds from offering total $16. 6 million in gross proceeds through the sale of common stock and prefunded warrants. Mar 19, 2020 · The gross proceeds to Aytu from this offering are expected to be approximately $20 million, before deducting the placement agent's fees and other offering expenses payable by Aytu. Find a participating Aytu RxConnect Pharmacy below. In addition, in the event the Jun 9, 2025 · Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA (TM Mar 3, 2022 · The gross proceeds from the Offering are expected to be approximately $7. Save Money With Limited Time Deals. (the “Company” or “Aytu”) (Nasdaq:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the launch of an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose The gross proceeds to Aytu from this offering are expected to be approximately $20 million, before deducting the placement agent's fees and other offering expenses payable by Aytu. Affordable. 50 each, raising approximately $14. 0001 per share ("Common Stock") at a public offering price of $1. (Nasdaq: AYTU) of Denver, Colorado. This represents significant dilution for existing shareholders but addresses immediate capital needs. Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and Stonepine Capital Management, with participation from Aytu management and new institutional shareholders Jun 10, 2025 · Gross proceeds from offering total $16. Jun 13, 2023 · Aytu BioPharma, Inc. patent overall covering the system's core oxidation-reduction potential (ORP) technology and its Aug 9, 2022 · / Aytu BioPharma, Inc. Jun 9, 2025 · Aytu BioPharma raised $16. announced the launch of an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, and accompanying warrants to purchase its common stock. 6 million through the sale of 3,030,000 shares of common stock and associated warrants. Lake Street Capital Markets served as the sole book-running manager for this offering. (AYTU) stock news and headlines to help you in your trading and investing decisions. The gross proceeds to Aytu from this offering are expected to be $20 million, before deducting the placement agent’s fees and other offering expenses payable by Aytu. Predictable If you’re commercially insured, you’re covered. 50 and 8,233,332 prefunded Jun 6, 2025 · AYTU, Financial) has expanded its previously announced stock offering from 6. Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and Get the latest Aytu BioPharma, Inc. Wall Street Analysts Forecast Based on the one-year price targets offered by 1 analysts Profit on the stock market by investing in biotech stocks Jun 6, 2025 · DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced the pricing of an upsized public offering of 9,600,000 shares of common stock (or prefunded warrants in lieu thereof) at an effective public offering price of $1. 00 implies 280% upside potential Gross proceeds from offering total $16. Jun 6, 2025 · Aytu BioPharma secured an upsized public offering of 9. Jun 6, 2025 · Aytu BioPharma has priced an upsized public offering of 9. The company achieved 32% revenue growth and $4. 50 and 8,233,332 prefunded In addition, Aytu has granted the underwriters a 30-day option to purchase up to an additional 1,440,000 shares of its common stock at the public offering price. Jun 30, 2025 · Ascendiant Capital Markets LLC Serves as Financial Advisor on $16,600,000 Public Offering for Aytu BioPharma, Inc. Its novel design uniquely serves patients and health care providers navigating their complex treatment journeys. *For eligible patients. 0 million through the sale of 21,505,814 shares of common stock and 1,750,000 pre-funded warrants. ENGLEWOOD, CO / ACCESSWIRE / August 8, 2022 / Aytu BioPharma, Inc. Analyst price target of $8. You’ll never pay more […] Jun 9, 2025 · DENVER, CO / ACCESS Newswire / June 9, 2025 / Aytu BioPharma, Inc. Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD Jun 9, 2025 · Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA (TM Jun 6, 2025 · Aytu Bioscience Inc. Certain information pertaining to use of the ofer will be shared with Aytu BioPharma, the sponsor of the ofer, and its afiliates. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the pricing of its underwritten public offering of (i) 21,505,814 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to Aytu BioPharma is a pharmaceutical company with a portfolio of commercial prescription therapeutics and consumer health products, and a growing therapeutics pipeline focused on treating rare Aug 8, 2022 · ENGLEWOOD, CO / ACCESSWIRE / August 8, 2022 / Aytu BioPharma, Inc. Ascendiant served as Financial Advisor on the transaction. , for, among other things, purported breaches of fiduciary duty and aiding and abetting fiduciary breaches, in connection with two transactions for which the plaintiff alleged Aytu overpaid Jun 6, 2025 · Aytu BioPharma (AYTU) has set the terms for its expanded public offering, detailing plans to release 9,600,000 shares of common stock at a price of $1. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the pricing of its underwritten public offering of (i) 21,505,814 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to 3 days ago · What's going on at Aytu BioPharma (NASDAQ:AYTU)? Read today's AYTU news from trusted media outlets at MarketBeat. Mar 31, 2025 · This Form 10-Q may refer to registered trademarks that we currently own or license, such as Aytu, Aytu BioPharma, Aytu RxConnect, Neos Therapeutics, Adzenys, Adzenys ER, Adzenys XR-ODT, Cotempla, Cotempla XR-ODT, Karbinal, Poly-Vi-Flor and Tri-Vi-Flor, which are protected under applicable intellectual property laws and are our property or the Jun 6, 2025 · In addition, Aytu has granted the underwriters a 30-day option to purchase up to an additional 1,440,000 shares of its common stock at the public offering price. In addition, Aytu has Jun 9, 2023 · Aytu BioPharma, Inc. 6 million shares of common stock. 74M shares. You’ll never pay more than […] JUPITER, Florida - June 10, 2025 -- Ascendiant Capital Markets LLC ("Ascendiant") announced today the closing of a $16,600,000 Public Offering financing for Aytu BioPharma, Inc. Predictable. 4 million upsized public offering to support the rollout. Oct 10, 2018 · Company Update ENGLEWOOD, CO / ACCESSWIRE / October 10, 2018 / Aytu BioScience, Inc. 9 million. Mar 12, 2020 · The gross proceeds to Aytu from this offering are expected to be $20 million, before deducting the placement agent's fees and other offering expenses payable by Aytu. 6 million public offering, which included the full exercise of the overallotment option. View real-time stock prices and stock quotes for a full financial overview. With the backing of Sterling Partners, Aytu Bioscience Inc. The funds will be used to advance pipeline assets, including the PREVEnt Trial for AR101, aimed at treating vascular Ehlers-Danlos Syndrome Jun 9, 2025 · Gross proceeds from offering total $16. (AYTU), closed an upsized offering of common stock and pre-funded warrants, raising gross proceeds of $16. Jun 9, 2025 · Aytu BioPharma recently closed an upsized public offering, raising $16. This is the first patent specifically covering fertility measurement methods with the MiOXSYS System and is the 15th U. market. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the launch of an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of Jun 23, 2025 · How much capital did Aytu BioPharma recently raise through its public offering? Aytu recently closed a $16. The funds will support the commercialization of EXXUA, a first-in-class FDA-approved RxConnect. Our unique prescription therapeutics help patients lead healthier and more fulfilling lives, with a distinct focus on complex central nervous system (CNS) conditions. The pre-funded warrants were exercised in full on August 11, 2022. 00, with a high estimate of 5. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the pricing of its underwritten public offering of (i) 21,505,814 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to Aug 9, 2022 · Aytu BioPharma, Inc. Aytu enters the over $22 billion United States prescription major depressive disorder ( "MDD Jun 9, 2025 · Gross proceeds from offering total $16. 50 and 8,233,332 prefunded Jun 9, 2023 · ENGLEWOOD, CO / ACCESSWIRE / June 9, 2023 / Aytu BioPharma, Inc. Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD Jun 6, 2025 · DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc. 0 Million Public Offering Priced At-The-Market and the Appointment of a New Director Aug 8, 2022 · ENGLEWOOD, CO / ACCESSWIRE / August 8, 2022 / Aytu BioPharma, Inc. OR > Learn more Additional Savings Offer If you can’t find an RxConnect Pharmacy near you, we still have you covered. Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and Stonepine Capital Management, with participation from Aytu management and new institutional shareholders Jun 9, 2023 · Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the launch of an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of Press Release – New York, NY – March 6, 2018 – Sichenzia Ross Ference Kesner LLP announced today that it has represented AYTU Bioscience, Inc. Mar 2, 2022 · Aytu BioPharma, Inc. (NASDAQ: AYTU) today announced the pricing of its equity offering co-led by Nantahala Capital Management and Stonepine Capital Management with participation by Armistice Aug 9, 2022 · ENGLEWOOD, CO / ACCESSWIRE / August 9, 2022 / Aytu BioPharma, Inc. The mission of Aytu “ A-2 ” BioPharma is to improve the lives of patients everywhere, with a distinct focus on complex CNS conditions. (NASDAQ: AYTU) (the "Company"), a specialty life sciences company focused on global commercialization of novel products in the ENGLEWOOD, CO, August 9, 2022 - Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the launch of an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of Aug 8, 2022 · Aytu BioPharma, Inc. 22 in the current market on the last check Thursday after announcing a public offering. , March 1, 2018 /PRNewswire/ -- Aytu BioScience, Inc. 0001 per share ("Common Stock") at a public Aug 15, 2022 · The aggregate gross proceeds from the Offering were $10. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the pricing of its equity offering co-led by Nantahala Jun 2, 2025 · Discover Aytu BioPharma's latest stock offering as they file to sell 6. The company’s portfolio includes a range of therapeutics that target a variety of medical conditions. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the launch of an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of Jun 9, 2025 · DENVER, CO / ACCESS Newswire / June 9, 2025 / Aytu BioPharma, Inc. EXXUA is set to launch in late 2025, targeting the $22 billion MDD market. ENGLEWOOD, CO, August 8, 2022 - Aytu BioPharma, Inc. (NASDAQ: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the placement to a healthcare-dedicated institutional investor in an underwritten offering of 3,030,000 shares of its common stock, pre-funded warrants to purchase up to 3,030,000 shares of its common stock, and Jun 6, 2025 · In addition, Aytu has granted the underwriters a 30-day option to purchase up to an additional 1,440,000 shares of its common stock at the public offering price. (Nasdaq: AYTU) $16,600,000 Public Offering - Ascendiant Capital MarketsWe provide equity capital, debt financing, and related strategic guidance and advisory services to public and private companies. (the “Company” or “Aytu”) (Nasdaq: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the launch of an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its Jun 6, 2025 · In addition, Aytu has granted the underwriters a 30-day option to purchase up to an additional 1,440,000 shares of its common stock at the public offering price. Click below to learn more. Aug 8, 2022 · Aytu BioPharma, Inc. 6 million from a public offering. S. In addition, Aytu has granted the Aytu BioPharma, Inc. today announced the pricing of its underwritten public offering of (i) 21,505,814 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 1,750,000 shares of its common stock. SUBJECT TO COMPLETION DATED JUNE 2, 2025 PRELIMINARY PROSPECTUS AYTU BIOPHARMA, INC. Jul 3, 2025 · On Monday, Aytu BioPharma, Inc. All Codes Verified. In addition, Aytu has granted the Jun 23, 2025 · Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, and those factors disclosed in Aytu's filings with the SEC, including Aug 8, 2022 · ENGLEWOOD, CO / ACCESSWIRE / August 8, 2022 / Aytu BioPharma, Inc. 00 and a low estimate of Mar 7, 2022 · Aytu BioPharma announced the closing of an underwritten offering, raising $7. 373 Inverness Parkway, Suite 206 Englewood, CO 80112 USA +1 (855) AYTU BIO (+1 855-298-8246) Jun 6, 2025 · The offering is expected to close on or about June 9, 2025, subject to the satisfaction of customary closing conditions. Mar 6, 2018 · ENGLEWOOD, Colo. Jun 9, 2025 · DENVER, CO / ACCESS Newswire / June 9, 2025 / Aytu BioPharma, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the closing of an underwritten public offering on October 9, 2018, with total gross proceeds of $15. RxConnect helps patients with commercial insurance pay as little as $0 for their COTEMPLA XR-ODT prescription* Find all the latest Aytu coupons, discounts, and promo codes at CouponAnnie in Apr 2024💰. , March 6, 2018 /PRNewswire/ -- Aytu BioScience, Inc. (NASDAQ: AYTU) (the "Company"), a specialty life sciences company focused on global commercialization of novel products in the Aug 9, 2022 · ENGLEWOOD, CO / ACCESSWIRE / August 9, 2022 / Aytu BioPharma, Inc. The Company expects to Aytu RxConnect is a network of pharmacies that provide affordable access to medications. 50 and 8,233,332 prefunded Aytu BioPharma is a specialty pharmaceutical company committed to improving the health and quality of life for patients everywhere. In addition, Aytu has granted the Sep 26, 2024 · Aytu BioPharma (AYTU) announces a $100M mixed shelf offering for sale of debt securities, common stock, preferred stock, warrants, rights, and units. , a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the placement to a healthcare-dedicated institutional investor in an Jun 9, 2025 · DENVER, CO / ACCESS Newswire / June 9, 2025 / Aytu BioPharma, Inc. Aytu RxConnect is a best-in-class patient access program that enables affordable, predictable patient access to Aytu’s portfolio of products. The offering included Common Warrants for an additional 23,255,814 shares. ENGLEWOOD, CO / ACCESSWIRE / March 2, 2022 / Aytu BioPharma, Inc. The Offering is expected to close on August 11, 2022, subject to the satisfaction of customary closing conditions. (Nasdaq: AYTU) April 30, 2025 Jun 9, 2025 · Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA™ Opportunity and Commercialization Plan Gross proceeds from offering total $16. Jun 10, 2025 · Aytu Biopharma CEO and CBO purchased a combined $125,000 in company shares on June 9th through the registered offering, signaling strong management confidence in the business. Jun 9, 2025 · Aytu BioPharma has closed an upsized at-the-market public offering, raising $16. Mar 1, 2018 · ENGLEWOOD, Colo. Jun 9, 2023 · ENGLEWOOD, CO / ACCESSWIRE / June 9, 2023 / Aytu BioPharma, Inc. mcdju xied sqbgq uya ektt njhr fwoc cgcjgnp orsue zjwx prtuezu hjmu yzxzm jvjjlr kucckh